西洛他唑联合丁咯地尔治疗2型糖尿病合并下肢动脉病变早期疗效观察

目的观察西洛他唑联合丁咯地尔治疗2型糖尿病并下肢动脉病变（PAD）早期疗效及不良反应。方法90例2型糖尿病并PAD早期（无伴下肢溃疡发生）患者随机分为治疗组50例和对照组40例。对照组在降糖治疗的基础上口服阿司匹林联合丁咯地尔;治疗组在降糖治疗的基础上口服西洛他唑联合丁咯地尔。疗程均为3个月。治疗前后分别检测主观症状及体征、间歇性跛行距离、踝肱指数（ABI）、脉搏波传播速度（PWV）等变化。结果治疗组与对照组ABI、PWV治疗后与治疗前比较,以及两组间治疗后比较,差异有显著意义（P〈0.01或P〈0.05）。治疗组PAD的总有效率与对照组比较,差异有显著意义（P〈0.05）。结论西洛他唑联合丁咯地尔治疗2型糖尿病并PAD早期效果显著,安全性好。

Cilostazol buflomedil joint clinical observation of treatment type 2 diabetes and the early effects of lower extremity arterial disease

Objective To view the joint cilostazol buflomedil treatment of type 2 diabetes and lower extremity arterial disease （PAD） of early efficacy and adverse reactions. Methods 90 cases of type 2 diabetes and early PAD （lower extremity ulcers occur unaccompanied） were randomly divided into treatment group 50 cases and 40 cases of the control group. Jiangtang treatment in the control group based on the combined oral aspirin buflomedil;hypoglycemie therapy in the treatment group based on the combined oral cilostazol buflomedil. Courses are for 3 months. Before and after treatment were detected by subjective symptoms and signs of intermittent claudication distance,ankle-brachial index （ABl）,pulse wave velocity （PWV） and other changes. Results The results of the treatment group and control group ABI,PWV after treatment compared with before treatment,as well as the 2 groups after treatment,the difference was significant （P〈0.01 or P〈0.05）. Treatment group the total effective rate of PAD compared with the control group,the difference was significant （P〈0.05）. Conclusion Cilostazol buflomedil joint treatment of type 2 diabetes and the early effects of PAD and safe is good.